Cost-effectiveness of expanding the target population of biennial screening for breast cancer from ages 50–69 to 45 and/or 74: A cohort modelling study in the Finnish setting

Table 2 Discounted individual outcomes and ICERs of expanded strategies compared to current strategy

Target pop. age	50–69		45–69		50–74		45–74
Perspective	Lim.Soc.	HC	Lim.Soc.	HC	Lim.Soc.	HC	Lim.Soc.	HC
Costs (€)	4 301	3 347	4 387	3 416	4 382	3 413	4 467	3 481
QALYs	21.855		21.860		21.857		21.861
LYG	24.027		24.032		24.029		24.034
ICER (€ per incremental QALY)			20 509	16 460	58 191	47 108	29 893	24 093

pop. population, Lim.Soc. limited societal, HC healthcare, LYG life years gained, QALYs quality-adjusted life years, ICER incremental cost-effectiveness ratio

ISSN: 2191-1991